苦参素联合胸腺肽治疗慢性乙型肝炎  

Kurorinone combined with thymus peptide in the treatment of chronic hepatitis B

作　　者：隋云华[1] 徐静[1] 郭银燕[1] 张馨[1] 李鑫[1] 

机构地区：[1]解放军第81医院肝病研究所,江苏南京210002

出　　处：《临床医学》2006年第10期17-18,共2页Clinical Medicine

摘　　要：目的探讨苦参素联合胸腺肽治疗慢性乙型肝炎的疗效，寻找治疗慢性乙型肝炎的有效方法。方法治疗组用苦参素葡萄糖注射液600mg，胸腺肽100mg，静脉注射，每日1次，使用12周后口服12周。对照组使用α干扰素500万U，皮下注射，隔日1次，胸腺肽100mg，肌肉注射，每周2次，用24周。两组患者均为乙型肝炎病毒单纯感染者。HB-sAg、HBeAg、HBcAb阳性，HBVDNA≥10^5拷贝／L。丙氨酸氨基转移酶（ALT）≥150U／L。结果治疗24周，苦参素组52例中39例（75．0％）ALT正常，干扰素组48例中38例（79．2％）ALT正常，差异无统计学意义（P〉0．05）。苦参素组HBeAg、HBVDNAM例（59．6％）转阴。干扰素组HBsAg转阴1例（2．1％），HBeAg27例转阴（56．2％），HBVDNA29例转阴，占60．4％。两组病原学比较，差异无统计学意义（P〉0．05）。停药随访12—24周，苦参素组31例近期治愈者18例（58．1％）复发，ALT升高，HBeAg和HBVDNA转阳。而干扰素组近期治愈的29例中10例（34．5％）ALT升高，HBeAg和HBVDNA转阳，X^2=1．09，P〉0．05。远期疗效比较，差异无统计学意义（P〉0．05）。结论苦参素与干扰素治疗慢性乙型肝炎，不论是近期还是远期疗效，差异均无统计学意义。在乙型肝炎的治疗中可以使用苦参素，但要延长疗程，和其他免疫调节剂联合使用，可能有增加疗效的作用。Objective To investigate the curative effect of kurorinone combined with thymus peptide in the treatment of chronic hepatitis B （ CHB）, in order to find out an effective method. Methods Group 1, including 52 hospital - patients, were given intravenous injection for 12 weeks using 600mg kurorinone and lOOmg thymus peptide, one time per day, then took orally for 12 weeks. Group 2 were taken interferon -α（INF） 5 000 000U, tertian subcutaneous injection, thymus peptide 100rag, intramuscular injection, 2 times per week for 24 weeks. All the patients were only infected with HBV, HBsAg / HBeAg / HBcAb positive, HBV DNA I〉 10s copy/L, ALTI〉 150U/L. Did contrastive research in these two groups. Results Mter twenty - four - week treatment, for group 1, the normalization rate of ALT was 75% （39/52 cases）. For group 2, the normalization rate of ALT was 79. 2% （38/48 cases） in the 24th week. The normalization rates of ALT of two groups were not different significantly （ P 〉 0.05）. For group 1, HBeAg and HBV DNA of 31 in 52 cases （59.6%） converted to negative. For group 2, HBsAg of 1 （2. 1% ） and HBeAg of 27（56. 2% ） and HBV DNA of 29（60. 2% ） in 48 cases （60.4%） converted to negative. The negative conversion rates of HBV DNA of two groups were not different significantly （ P 〉 0. 05 ）. After halting treatment and follow - up study for 12 -24 weeks, for group 1, CHB of 18 in 31 （58.1%） patients who were cured in the near future recrudesced, ALT mounted up, HBeAg and HBV DNA converted to positive. For group 2, CHB of 10 in 29 （34.5%） patients who were cured recently now recrudesced. The long - dated effect wasnt different significantly （ X2 = 1.09, P 〉 0.05 ）. Conclusion There is no significant difference in the treatment of CHB using between kurorinone and interferon, whatever in the near future or long - dated. We can use kurorinone for the treatment of CHB, but should prolong the period of treatment and combining with other immunomodulator,under this state th

关 键 词：乙型病毒性肝炎 苦参素 干扰素 

分 类 号：R512.62[医药卫生—内科学]